ST-segment Elevation Myocardial Infarction (STEMI)
1
Pipeline Programs
4
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Boston ScientificNo aspirin
MedtronicExport Catheter
Autonomous TherapeuticsThrombus aspiration
Clinical Trials (3)
Total enrollment: 6,396 patients across 3 trials
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Start: Feb 2023Est. completion: Jan 20282,258 patients
Phase 4Recruiting
Use of Export in Primary Percutaneous Coronary Intervention
Start: Jan 2024Est. completion: May 2026300 patients
N/AActive Not Recruiting
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
Start: Aug 2020Est. completion: Feb 20263,838 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 6,396 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.